Mermaid Bio GmbH

Mermaid Bio’s mission is to discover and develop breakthrough intrabodies (antibodies for intracellular targets) to treat unmet patient needs. We link single domain antibodies (nanobodies) together with advancements in drug delivery (using mRNA/LNP systems) to create a proprietary platform capable of producing breakthrough medicines.

https://mermaid.bio

2-10 employees

Growth Trajectory

While Mermaid Bio is in liquidation, there's potential growth through licensing or acquisition of their intrabody technology and assets. Further development of their targeted delivery methods and single-domain antibody platform presents innovation opportunities for interested parties. This also represents a partnership opportunity for companies seeking to expand their precision medicine capabilities.

Technical Challenges

Tech Stack

Team Size

Key Risks

Liquidation status poses a significant risk to the company's immediate operations and future prospects.

Reliance on a single lead program (ABC) creates vulnerability if that program faces setbacks.

Market adoption of intrabody technology may face regulatory hurdles or require extensive clinical validation.

Opportunities

Licensing or acquiring Mermaid Bio's technologies and assets at potentially favorable terms due to liquidation.

Further development of Intrabody technology for diverse therapeutic applications.

Partnerships with pharmaceutical companies seeking advanced drug delivery systems.

Live Data Stream

Access Our Live VC Funding Database

30,000+ funded startups

tracked in the last 3 months

B2B verified emails

of key decision makers

Growth metrics

Real-time company performance data

Live updates

of new VC funding rounds

Advanced filters

for sophisticated queries

API access

with multiple export formats

Access Database

Updated every 5 minutes